Anelixis Therapeutics to Provide Pipeline of Clinical Candidates for ALS

Steve Perrin, Ph.D., CEO of ALS Therapy Development Institute and CEO of Anelixis Therapeutics, to present at the 16th annual BIO CEO & Investor Conference

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
Anelixis is a totally new concept in drug development leveraging a decade of preclinical data from ALS TDI to advance potentially transformational medicines for patients today forward.

CAMBRIDGE, MA (PRWEB) February 10, 2014

The ALS Therapy Development Institute (ALS TDI) announced today that its CEO and CSO, Steve Perrin, Ph.D., who also serves as the CEO of the Institute’s wholly-owned subsidiary, Anelixis Therapeutics, will present at the 16th Annual BIO CEO & Investor Conference at the Waldorf Astoria New York. Dr. Perrin will provide an update on Anelixis’ pipeline of candidate therapeutics targeting ALS, also known as Lou Gehrig’s disease. This pipeline includes products targeting the immune system and misfolded proteins.

ALS TDI formed the virtual biotechnology company, Anelixis Therapeutics, in 2013 to attract angel and venture funding unavailable to the nonprofit in order to advance its mission. Anelixis is actively seeking investors to join in the funding of these projects.

“People living with ALS are in desperate need of effective treatments,” says Dr. Perrin. “Anelixis is a totally new concept in drug development leveraging a decade of preclinical data from ALS TDI to advance potentially transformational medicines for patients today forward.”

In addition to updates on Anelixis’ pipeline of clinical candidates for ALS, Dr. Perrin will also provide new information about ALS TDI’s Phase IIA clinical trial on Novartis’ Gilenya® in ALS and an overview of preclinical candidates being explored.

Dr. Perrin will present at 11:00 a.m. on Monday, February 10 in room Park South on the fourth floor.

About ALS Therapy Development Institute (ALS TDI)
The mission of the ALS Therapy Development Institute (ALS TDI) is to discover and develop effective treatments to end ALS as soon as possible. ALS TDI is the world’s largest independent ALS/MND drug development-focused nonprofit organization. It currently has partnerships with dozens of pharmaceutical and biotechnology companies worldwide in order to advance potential treatments into the clinic. Its lead ALS therapeutic candidate, Novartis’ (Switzerland) Gilenya (TDI-132), is in Phase 2A clinical trial for ALS. For more information, visit http://www.als.net.

About Anelixis Therapeutics
Anelixis Therapeutics is a mission-aligned translational medicine and drug development company created by the ALS Therapy Development Institute in 2013. It uses innovative business models as a virtual biotech to advance potential ALS treatments, licensed from the Institute and other like-minded organizations, through early stage clinical development, adding value to the most promising lead candidates and preparing them for later stage development together with larger biotechnology and pharmaceutical companies. For more information, visit http://www.AnelixisTherapeutics.com or contact 617-599-6514.

About the BIO CEO & Investor Conference
The 16th Annual BIO CEO & Investor Conference is the largest independent investor conference focused on publicly-traded biotechnology companies. The conference is designed to foster an informative dialogue between institutional investors and senior biotechnology executives about emerging and current investment opportunities. The 2013 CEO & Investor Conference featured 1,380 partnering meetings, 148 company presentations, and 1,400 attendees, over half of which were investors.

Media Contact
Rob Goldstein, ALS TDI, 617-441-7295, rgoldstein(at)als(dot)net


Contact